Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) and Avantor (NYSE:AVTR – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.
Volatility and Risk
Maravai LifeSciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Avantor has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Maravai LifeSciences and Avantor, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Maravai LifeSciences | 2 | 0 | 2 | 0 | 2.00 |
| Avantor | 1 | 15 | 2 | 0 | 2.06 |
Earnings and Valuation
This table compares Maravai LifeSciences and Avantor”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Maravai LifeSciences | $185.74 million | 10.09 | -$130.77 million | ($0.52) | -13.88 |
| Avantor | $6.55 billion | 1.44 | -$530.20 million | ($0.84) | -16.63 |
Maravai LifeSciences has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
50.2% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 95.1% of Avantor shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 0.3% of Avantor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Maravai LifeSciences and Avantor’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Maravai LifeSciences | -37.07% | -15.70% | -8.17% |
| Avantor | -8.81% | 9.92% | 4.75% |
Summary
Avantor beats Maravai LifeSciences on 7 of the 13 factors compared between the two stocks.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
About Avantor
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
